UAE doctors successfully treat rare inflammatory diseases for first time

Abu Dhabi: Tawam Hospital, part of SEHA under PureHealth, has successfully administered a groundbreaking therapy for rare inflammatory conditions, marking a first in the UAE and the wider GCC.

The innovative treatment uses the biologic drug Rilonacept to treat idiopathic recurrent pericarditis and Adult-Onset Still’s Disease (AOSD), helping two young Emirati patients recover from previously treatment-resistant conditions.

Targeting inflammation at the source

Rilonacept works by inhibiting interleukin-1, a key protein driving inflammation. The therapy alleviates severe symptoms including recurring fever, pain, shortness of breath, rash, and swelling, improving clinical outcomes and quality of life for patients.

Fast-tracked approval for timely access

The Department of Health – Abu Dhabi fast-tracked the drug’s approval, assigning a unique identification code after evaluation by a multidisciplinary Life Sciences team. This ensures patients with insurance coverage can access innovative treatments promptly, strengthening the emirate’s healthcare system.

Abu Dhabi’s hub for advanced care

Dr. Khalid Abdullah Alnaqbi, Head of Rheumatology at Tawam Hospital, said the achievement demonstrates the hospital’s growing role as a regional center of excellence in complex autoimmune and rheumatic diseases. Dr. Dalal Al Mansoori, Executive Medical Director, added that providing advanced treatments locally showcases Abu Dhabi’s ability to deliver world-class, patient-centered innovation on its own soil.